Navigation Links
Columbia study shows widely used artery clearing device does not help patients during heart attack

Interventional cardiologists from Columbia University Medical Center have shown that a commonly used procedure to remove fatty debris from blocked arteries during a heart attack does not improve patient outcomes.

The procedure, called distal microcirculatory protection, is commonly and successfully used during angioplasty in vein grafts and stenting in carotid arteries. The study, published in the March 2 issue of the Journal of the American Medical Association, found that the devices were successful in removing debris from the arteries in angioplasties during heart attacks, but it showed that there was no benefit to the patient.

"It's not entirely clear why the devices failed to improve patient outcomes, but it's possible that so much damage happens during a heart attack that distal protection is simply too little, too late," said Gregg W. Stone, M.D., director of research and education for the Center for Interventional Vascular Therapy at Columbia University Medical Center and New York-Presbyterian Hospital, and vice chairman of the Cardiovascular Research Foundation.

The study, which was conducted in 38 institutions in seven countries, examined 501 patients who were having heart attacks, half of whom received distal protection.

During angioplasty procedures, fatty deposits in the arteries can be dislodged and clog arteries further downstream. Distal protection devices use a specialized guidewire and catheter to collect and remove this debris.

The study evaluated the efficacy of distal protection devices using several measures, including evaluating patient ST segments ?a portion of the EKG that can indicate heart damage when it is elevated. The study showed that the percentage of patients who had normalization of the ST segment were the same, whether or not distal protection devices were used.

Within six months of the heart attack, patients had a comparable frequency of major adverse cardiac events regardless of wheth er or not they received the treatment.

The study also measured the size of the heart attacks by measuring the uptake of a tracer in the heart, and found that there was no difference for patients who received distal protection.

According to Dr. Stone, not using distal protection devices will reduce the cost of angioplasties during heart attacks, and could avoid potential complications caused by the devices.


'"/>

Source:Columbia University Medical Center


Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. Columbia scientists develop cancer terminator viruses
3. Contaminants linked to sturgeon decline in Columbia river
4. Columbia University licenses next-generation DNA sequencing technology
5. New bird discovered on unexplored Columbian mountain
6. Columbia scientists determine 3-dimensional structure of cells fuel gauge
7. Bioartificial kidney under study at MCG
8. W.M. Keck Foundation funds study of friendly microbes
9. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
10. Genome-wide mouse study yields link to human leukemia
11. Clam embryo study shows pollutant mixture adversely affects nerve cell development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma ... Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, ... Perkins joins Pennside after more than a decade with leading market research firm, ...
(Date:2/21/2017)... Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... ended December 31, 2016. SQI is a ... that develops and commercializes proprietary technologies and products for advanced ... ... achieved in fiscal 2016," said Andrew Morris , SQI,s ...
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer diagnostics workflow solution provider ... executive team to lead the development and commercialization of its Cancer Information Data ... diagnosis and treatment of cancer. The CIDT addresses the need for curated and ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... transformative design and manufacturing solutions for original equipment manufacturers (OEMs) , today announced ... marks Creation Technologies’ third consecutive year winning in its category of electronics manufacturing ...
Breaking Biology Technology: